Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis by Lin, Kevin Y. et al.
 Nanoparticles That Sense Thrombin Activity As Synthetic Urinary
Biomarkers of Thrombosis
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Lin, Kevin Y., Gabriel A. Kwong, Andrew D. Warren, David K.
Wood, and Sangeeta N. Bhatia. 2013. “Nanoparticles That Sense
Thrombin Activity As Synthetic Urinary Biomarkers of
Thrombosis.” ACS Nano 7 (10): 9001-9009.
doi:10.1021/nn403550c. http://dx.doi.org/10.1021/nn403550c.
Published Version doi:10.1021/nn403550c
Accessed February 19, 2015 2:41:37 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11878910
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAA
LIN ET AL. VOL. 7 ’ NO. 10 ’ 9001–9009 ’ 2013
www.acsnano.org
9001
September 09, 2013
C 2013 American Chemical Society
Nanoparticles That Sense Thrombin
Activity As Synthetic Urinary
Biomarkers of Thrombosis
Kevin Y. Lin,†,[ Gabriel A. Kwong,‡,§,[ Andrew D. Warren,‡,§ David K. Wood,‡,§,^ and
Sangeeta N. Bhatia‡,§, ),#,r,X,*
†Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States, ‡HarvardMIT Division of Heath
Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States, §Institute for Medical Engineering and Science,
Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States, ^Department of Biomedical Engineering, University of Minnesota,
Minneapolis, Minnesota 55455, United States, )Electrical Engineering and Computer Science, David H. Koch Institute for Integrative Cancer Research, Massachusetts
Institute of Technology, Cambridge, Massachusetts 02139, United States, #Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02139, United States,
rDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States, and XHoward Hughes Medical Institute, Cambridge,
Massachusetts 02139, United States. [K. Y. Lin and G. A. Kwong contributed equally.
U
rine analysis has a rich and long-
standing clinical history as a tool for
monitoring health and disease and
remains an integral component of amedical
examination.13Well over 100 tests canbeper-
formed to indicate conditions as diverse as pre-
gnancy,4,5 diabetes,69 kidney diseases,1012
metabolic disorders,13,14 and others. Re-
cently, the discovery of urinary analytes that
were previously thought to be present
mainly in circulating blood because of their
large hydrodynamic radii (e.g., enzymes,
exosomes and others) has expanded the
diagnostic repertoire to include urinary bio-
markers against diseases of distant organs
such as breast and brain cancer.15,16 In-
spired by the elegant physiology of the
renal system, which has evolved the capa-
city to selectively ﬁlter liters of blood to
remove byproducts of biological processes
within minutes, we recently developed a
class of protease-sensitive nanoparticles,
called “synthetic biomarkers”, that in re-
sponse to dysregulated protease activity at
the sites of disease, release reporters into
the circulation that are then concentrated
into the host urine for noninvasive mon-
itoring.17 In murine models of liver ﬁbrosis
and cancer, we showed that synthetic uri-
nary biomarkers have the potential to non-
invasively monitor solid organs and improve
early stage detection of cancer compared to
tumor-secreted blood biomarkers.
Here we hypothesized that synthetic bio-
markers could be tailored to survey intra-
vascular sites for acute thrombosis, the
activation of a cascade of protease activity
that orchestrates the formation of obstructive
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ABSTRACT Thrombin is a serine protease and regulator of hemostasis
that plays a critical role in the formation of obstructive blood clots, or
thrombosis, that is a life-threatening condition associated with numerous
diseases such as atherosclerosis and stroke. To detect thrombi in living
animals, we design and conjugate thrombin-sensitive peptide substrates to
the surface of nanoparticles. Following intravenous infusion, these
“synthetic biomarkers” survey the host vasculature for coagulation and,
in response to substrate cleavage by thrombin, release ligand-encoded
reporters into the host urine. To detect the urinary reporters, we develop a
companion 96-well immunoassay that utilizes antibodies to bind speciﬁcally to the ligands, thus capturing the reporters for quantiﬁcation. Using a
thromboplastin-induced mouse model of pulmonary embolism, we show that urinary biomarker levels diﬀerentiate between healthy and thrombotic
states and correlate closely with the aggregate burden of clots formed in the lungs. Our results demonstrate that synthetic biomarkers can be engineered to
sense vascular diseases remotely from the urine and may allow applications in point-of-care diagnostics.
KEYWORDS: synthetic biomarkers . nanoparticles . peptides . thrombin . urinary diagnostic
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blood clots within vessels (Figure 1A). Thrombi are a
critical pathophysiological feature of numerous vascu-
lar diseases including acute coronary syndrome, stroke,
and venous thromboembolism.18 The most important
serine protease in the coagulation cascade is thrombin,
which not only catalyzes the conversion of ﬁbrinogen
to ﬁbrin that serves as the structural scaﬀold of a clot,
but also regulates hemostasis through positive and
negative feedback circuits.19,20 To date, a number of
studies have described the use of near-infrared ﬂuoro-
genic probes to detect thrombin activity in the setting
of thrombus formation as well as other thrombin-
dependent diseases such as atherosclerosis.2123 More
recently, these probes have been modiﬁed to include
cell penetrating mechanisms that are activated after
cleavage to improve the retention of the imaging
agent and maintenance of the detection signal.23,24
In the clinic, blood biomarkers such as prothrombin
fragment 1.2 (a byproduct of prothrombin cleavage
into thrombin) and D-dimer (a byproduct of ﬁbrin
degradation) are often used as indicators of thrombo-
sis; however, these tests are highly susceptible to
artifacts introduced by a blood draw, have poor speci-
ﬁcity, and more accurately reﬂect upstream or down-
stream cleavage events (i.e., Factor Xa activation of
prothrombin or plasmin activity during ﬁbrinolysis,
respectively) rather than thrombin activity.2527 In this
report, we engineer nanoparticles that survey the host
vasculature for thrombi and,17,28 in response to throm-
bin activity, release reporters into the urine as an
integrated measure of the aggregate burden of sys-
temic clots. We describe a method to encode these
reporters with structurally distinct ligands that allow
antibody-based detection by enzyme-linked immuno-
sorbent assay (ELISA) in standardized 96-well plates
that makes this platform readily amenable for use in
clinical laboratories.
RESULTS AND DISCUSSION
Engineering Thrombin-Sensitive Synthetic Biomarkers. The
construction of synthetic biomarkers for thrombosis
involves modifying the surface of iron oxide nano-
worms (NW), a nanoparticle formulation previously
developed by our collaborators,29,30 with substrate-
reporter tandem peptides that are cleavable by throm-
bin and detectable by ELISA (Figure 1A). NWs were
chosen for their safety profile and large hydrodynamic
diameter (∼40 nm, Figure S1A, Supporting Information),
which prevents surface-conjugated peptides from fil-
tering directly into the urine (∼5 nm glomerulus size-
exclusion limit) before cleavage.17,28 To first develop a
suitable substrate, we extended the thrombin cleava-
ble sequence fPRxS (x = site of cleavage, kcat/Km ∼
9.33  106)3134 to include glycine spacers and a
C-terminal cysteine to allow coupling to NWs via
sulfhydryl chemistry.30 To test substrate specificity,
we conjugated fluorophore-labeled derivatives onto
NWs (sequence = (K-Flsc)GGfPRSGGGC, Figure S2A,
Supporting Information) at a valency (∼40 peptides
per NW by absorbance spectroscopy, Figure S1B,
Figure 1. (A) Schematic of approach. Synthetic biomarkers composed ofNWs conjugatedwith a thrombin-sensitive substrate
in tandemwith a ligand-encoded reporter. These agents survey the vasculature for the sites of clot formationwhere thrombin
activity cleaves and releases the reporters into urine for analysis by ELISA. (B) Schematic of ﬂuorogenic NWassay for detecting
protease activity. (C) Kinetics of ﬂuorogenesis produced by the activity of thrombin (red) and other coagulation proteases
(n = 3 per condition). Thr, thrombin; Bival, bivalirudin. (D) Kinetics of ﬂuorogenesis in plasma after the addition of CaCl2 to
activate coagulation (n = 3 per condition).
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Supporting Information) sufficient to reduce fluores-
cence by over 90% via homoquenching (Figure S1C,
Supporting Information) and then incubated the NWs
(200 nM by peptide, 5 nM by NW) with purified
thrombin (2 μM) or a panel of blood clotting proteases
(FXa (160 nM), APC (60 nM), FIXa (90 nM), FVIIa (10 nM),
FXIa (31 nM)), each present at itsmaximal physiological
concentration (Figure 1B). Freely emitting peptide
fragments that were released by thrombin activity
rapidly increased sample fluorescence (red, Figure 1C).
By contrast, negligible proteolysis was observed from
the panel of noncognate proteases, as well as by
thrombin in the presence of bivalirudin (Bival), a
clinically approveddirect thrombin inhibitor. To further
investigate the ability to sense thrombin activity from
blood, we spiked NWs into human plasma samples
inactivated with sodium citrate (an anticoagulant that
chelates the cofactor calcium) and monitored plasma
fluorescence after the addition of excess calcium
chloride (CaCl2) to trigger coagulation, or phosphate
buffered saline (PBS) as a control. Aligned with our
previous observations with purified enzymes, plasma
fluorescence markedly increased upon activation of
the clotting cascade but not in control samples or in
the presence of bivalirudin (Figure 1D). To test stability,
we incubated fluorogenic NWs in 10% serum at 37 C
overnight and did not detect any significant differ-
ences in size (Figure S1D, Supporting Information) that
would indicate precipitation or increases in sample
fluorescence (Figure S1E, Supporting Information) that
would indicate nonspecific substrate cleavage. Collec-
tively, these results established the ability of our NWs
to specifically sense the proteolytic activity of thrombin
within the complex milieu of plasma, consistent with
previously described thrombin-specific fluorogenic
probes.22
Detection of Ligand-Encoded Reporters by ELISA. We next
set out to build a system of ligand-encoded reporters
that would allow quantification of protease activity in a
96-well format by ELISA, the primary detection plat-
form for many clinical tests. Conventional ELISAs de-
tect a target analyte via a sandwich complex com-
posed of two affinity agents that bind to distinct
epitopes on the analyte (Figure 2A). To build a synthetic
reporter, we modified the protease-resistant peptide
Glutamate-Fibrinopeptide B (Glu-fib, sequence =
eGvndneeGffsar, lower case = D-isomer), which we
selected for its high renal clearance efficiency,35 at
the termini with structurally distinct ligands (i.e., Flsc
or AF488) and biotin (labeled R1 and R2 respectively;
Figure 2A). To test the immunoassay, these reporters
were then spiked into urine and applied to 96-well
plates precoated with capture antibodies (R-Flsc or
R-AF488) before the presence of R1 or R2 was detected
by the addition of neutravidin-horseradish peroxidase
(HRP) and its catalytic development of 3,30,5,50-tetra-
methylbenzidine (TMB). As predicted from the specifi-
cities of the antibodies, a significant change in color
appeared only in wells containing matched antibody-
ligand pairs (þ/ or/þwells, Figure 2B) and was not
affected by the presence of noncognate reporters
(þ/þ wells). Identical trends were observed at the limits
of detection for both capture antibodies (∼3 pM,
Figure 2C, Figure S3, Supporting Information), indicating
Figure 2. Designing ligand-encoded reporters for detection by ELISA. (A) Schematic of ligand-encoded reporters R1 and R2
alongwith chemical structures of associated ligands. (B) Schematic of ELISA sandwich complex and photograph of developed
96-well plates showing speciﬁc detection of R1 andR2 spiked into control urine samples. (C) Absorbance values (λ=450nm) of
wells coatedwith anti-Flsc antibodies used to detect serial dilutions of R1, R1þ R2, and R2 in urine (n=3 per condition, s.d.). (D)
Quantiﬁcation of the level of cleaved reporters (R1) released from NWs after incubation with increasing concentrations of
thrombin (n = 3 per dose, s.d.).
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that our synthetic reporters were detected with high
specificity and sensitivity comparable with protein-
based ELISAs.36 With an optimized thrombin substrate
and a reporter system in place, we then incubated NWs
(100 nM by peptide, 2.5 nM by NW) decorated with our
final tandem peptide construct (sequence = biotin-
eGvndneeGffsar(K-Flsc)GGfPRSGGGC, Figure S2B, Sup-
porting Information) with increasing levels of thrombin
and found that the amount of cleavage products
released into solution (isolated by size filtration) was
dose dependent, reaching a plateau likely due to
cleavage of all available substrates and establishing
our ability to monitor thrombin activity by ELISA
(Figure 2D). Collectively, these results indicate that
the specificity of ligandantibody interactions can be
used to build panels of orthogonal reporters for monitor-
ing protease activity by standardized 96-well assays.
Characterization of Thromboplastin-Induced Pulmonary Em-
bolism. Wenext investigated the ability of our synthetic
biomarkers to detect thrombosis in living mice in-
duced via intravenous (i.v.) administration of thrombo-
plastin. This model has been used in the hematology
literature to explore the role different vascular recep-
tors play in host susceptibility to thrombosis and to
probe the efficacy of new antithrombotic agents.3739
Thromboplastin triggers the clotting cascade through
the extrinsic pathway via complexation of tissue factor
and factor VII, and blood clots embolize to the lungs in
this model, recapitulating the life-threatening clinical
condition of pulmonary embolism (PE). To quantify PE
formation, we coinjected mice with thromboplastin
and the clot precursor fibrinogen labeled with the
near-infrared fluorophore VT750 so that the formation
of fibrin clots by thrombin-mediated proteolysis of
fibrinogen could be quantified by fluorescent analysis
of whole organs (Figure 3A). Within 30 min of admin-
istration, we observed a more than 6-fold increase in
the level of fibrin(ogen) depositedwithin the lungs and
significant decreases in the kidneys and liver (P < 0.005
by Student's t-test, n = 3 mice; Figure 3B), consistent
with venous blood flow patterns that transport throm-
bi formed upon i.v. administration directly to the lungs
from the heart, leading to depletion of VT750-fibrino-
gen in the other organs. Histochemical analysis of
tissue sections corroborated these findings by reveal-
ing the presence of blood clots in lung sections (blue
arrow, Figure 3C) that were absent in the other major
organs (brain, heart, kidney, liver and spleen; Figure S4,
Supporting Information) and in control animals.
Animals given escalating but sublethal doses (observed
Figure 3. Induction of thrombosis by thromboplastin. (A) Near-infrared ﬂuorescent scans of excised organs to monitor the
deposition of VT750-labeled ﬁbrinogen following intravenous administration of thromboplastin (2 μL/g of body weight) or
PBS. (B) Quantiﬁcation of the level of VT750-ﬁbrin(ogen) deposited in organs harvested from thrombosis and control mice
(*P<0.05, **P<0.01, ***P<0.005, Student's t-test;n=3per group, s.d.). (C) Hematoxylin and eosin stainingof lungs harvested
from thrombosis andhealthymice (scale bar = 100μm). Blue arrowdenotesﬁbrin clot. (D) Quantiﬁcation ofﬁbrin deposited in
the lungs in response to escalating doses of thromboplastin. Bival, bivalirudin (*P < 0.05, **P < 0.01, ***P < 0.005, one-way
ANOVA with Tukey post-test; n = 35 mice, s.e.).
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LD50 ∼ 3 μL per g b.w.) of thromboplastin accumu-
lated fibrin(ogen) in the lungs in proportion to the
dosage, and PEs were readily prevented in animals
pretreated with bivalirudin (P < 0.005 by one-way
ANOVA with Tukey post-test, n = 35 mice; Figure 3D,
Figure S5, Supporting Information), confirming that
clot formation is largelydrivenby theactivityof thrombin.
Altogether, these results established our ability to pre-
cisely control total clot burden in amodel that resembles
the clinical pathology of venous thrombosis.38,40
Detection of Pulmonary Embolism from Urine. Next, we
characterized the pharmacokinetics of our synthetic
biomarkers in the context of thrombosis. We injected
mixtures of VT750-labeled NWs and thromboplastin
into mice and observed no significant differences in
NW distribution between the thromboplastin and
control groups in all of the excised organs, including
the lungs, indicating that thrombosis did not alter the
biodistribution of the NW scaffold (P > 0.05 by
Student's t-test, n = 3 mice; Figure 4A, Figure S6,
Supporting Information). To monitor peptide cleavage
and trafficking of the cleaved fragments, we coadmi-
nistered NWs conjugated with fluorescently quenched
substrates and observed significant increases in fluo-
rescence in the lungs and kidneys by ∼1.8 and ∼2.5
fold over healthy animals, respectively (P < 0.01 by
Student's t-test, n = 3 mice; Figure 4B, Figure S7,
Supporting Information). Paired with our earlier
observations showing that thromboplastin did not
alter the biodistribution of the NWs and induced blood
clots that were localized to the lung (i.e., clots were not
found in the kidneys), this finding provided evidence of
peptide cleavage in the lungs and kidney accumula-
tion of freely emitting fluorescent fragments. Immuno-
fluorescent staining of lung sections further showed
NW (green) localization with fibrin (red) at the sites of
coagulation, which was absent in control sections
(Figure S8, Supporting Information), supporting our
hypothesis that circulating NWs can access local
thrombi. To visualize the clearance efficiencies of the
peptide fragments, we monitored mice by in vivo
fluorescence imaging and observed a strong increase
in fluorescent signal that was localized to the bladder
of thrombotic mice relative to controls (Figure 4C). Taken
together, our data illustrated that our synthetic biomark-
ers can systemically survey the vasculature for thrombin
activity and release reporters at sites of thrombosis,which
are then cleared efficiently into the host urine.
In considering clinical translation,we sought to develop
a method to account for variations in the production
rate of urine expected in individuals that could aﬀect
the urine concentration of our reporters. Urinary pro-
duction rates are mainly dependent on the hydration
state of the host (ranging from 501200 mOsm/kg of
H2O in humans)
41 and aﬀected by many external
factors (e.g., circadian rhythm, diet, activity, and others).
Figure 4. Noninvasive urinary detection of pulmonary embolism (A) Quantiﬁcation of the distribution of VT750-labeled NWs
in organs excised frommice treatedwith thromboplastin or PBS (n=3mice, s.d.). (B) Quantiﬁcation of theﬂuorescent signal of
organs after mice were infused mixtures of NWs conjugated with quenched substrates (labeled with VT750) and
thromboplastin or PBS (**P < 0.01, Student's t-test; n = 3 mice, s.d.). Inset shows representative ﬂuorescent scans of the
kidneys and the lungs. (C) In vivo ﬂuorescent image after administration of NWs showing increased ﬂuorescent signal
localized to the bladders ofmice challengedwith thromboplastin. (D) Normalized urinary reporter levels (R1/R2) from healthy
mice (day 0) and in response to thromboplastin and bivalirudin (day 5). Bival, bivalirudin (***P < 0.005, two-way ANOVAwith
Bonferroni post-test; n = 5 mice, s.e.). (E) Correlation plot of the clot burden in the lungs versus urinary biomarker levels
(Pearson's r = 0.999; n = 510 mice, s.e.).
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Approaches to determine the concentration of urine
include measuring the level of creatinine,42,43 a bypro-
duct of muscle metabolism that ﬁlters into the urine at
a steady state when at rest, or i.v. administration of
inulin,4446 a polysaccharide that is not actively ab-
sorbed or secreted by the kidneys and whose appear-
ance in urine is directly related to the rate of urine
production. Motivated by the clinical precedent set by
inulin, we hypothesized that because our free reporters
(R1, R2) are built from Glu-ﬁb, which is likewise biolo-
gically inert,35 their ﬁltration into urine following i.v.
administration would be indicative of the concentra-
tion of urine. To test this, we excessively hydrated a
cohort of mice with a subcutaneous bolus of saline
equivalent to 10% of their body weight followed by i.v.
administration of free R2. Compared to control mice
infused with R2 only, hydrated mice produced over 2.5
foldmore urinewithin 2 h (P < 0.005 by Student's t-test,
Figure S9A, Supporting Information) and their urinary
concentration of R2 decreased by ∼50% (P < 0.005 by
Student's t-test, Figure S9B, Supporting Information),
showing that our free reporters could be used to
monitor the hydration state and urine concentration
of the animals. We next sought to monitor thrombo-
plastin-induced PEs by urine analysis of the response of
our synthetic biomarkers to thrombin activity. To
simulate serial monitoring that frequently occurs in
inpatient settings, we ﬁrst determined the basal activ-
ity in healthy cohorts of animals each receiving thrombin-
sensitive NWs and a free reporter (R2) for urine normal-
ization (Figure 4D). After ﬁve days to allow NWs to fully
clear (half-life ∼6 h),17 we administered a mixture of
thromboplastin, NWs, and R2 into the same mice and
quantiﬁed reporter levels by ELISA. When compared to
their healthy state (day 0), the induction of PEs (day 5)
resulted in signiﬁcant elevations in the level of urinary
cleavage fragments by up to 3-fold (P < 0.005 by two-
way ANOVA with Bonferroni post-test, n = 5 mice;
Figure 4D). In mice treated with bivalirudin prior to
thrombotic challenge (dose = 2 μL per g of b.w.),
reporter levels were abrogated, consistent with our
earlier ﬁndings showing the ability of bivalirudin to
inhibit thrombin activity and prevent the formation of
PEs. When the urinary biomarker marker levels from
thromboplastin-challengedmiceweredirectly compared
to the amount of ﬁbrin(ogen) deposited at identical
doses of thromboplastin (Figure 3D), we found a striking
correlation to the disease burden with a correlation
coeﬃcient of 0.99 (Pearson's r, Figure 4E). Collectively,
our ﬁndings showed that synthetic biomarkers can
monitor thrombin activity in living mice and quantita-
tively measure the aggregate burden of sublethal PEs
from the urine by ELISA.
CONCLUSION
By harnessing the capacity of peptide-decorated
NWs to circulate and sense their local vascular
microenvironment, we have engineered synthetic bio-
markers that can detect thrombin activity in vivo and
noninvasively quantify the aggregate amount of active
clots. Unlike other nanoparticle sensors that function
by producing a localized signal,2124,4749 our NWs
sense protease activity by releasing reporters locally at
the sites of thrombus formation but are then ﬁltered
and detected remotely from the urine. Interestingly, in
imaging studies using ﬂuorogenic thrombin-cleavable
probes, this “washout” of the cleaved fragments was
also directly observed by monitoring the attenuation
of the strength of the detection signal localized at the
thrombi.21 Similar to circulating biomarkers, our ap-
proach can reveal thrombosis at sites deep within the
body, such as the lungs, that are diﬃcult to detect with
ﬂuorogenic probes because of tissue absorption and
scattering of light.50 This property allows urine analysis
to integrate and quantitatively assess the burden of
vascular clots, which would otherwise require systemic
exploration by imaging. In addition, we developed a
panel of heterobifunctional reporters that can be
detected by standardized 96-well plate assays, remov-
ing the need for mass spectrometry as described in our
previous study.17 This reporter system is readily exten-
sible by incorporating additional ligand-capture agent
pairs and is amenable for detection by other methods
including paper-based tests at the point of care.5153
Potential improvements to this platform include the
use of new thrombin-sensitive substrates that are
signiﬁcantly more speciﬁc to reduce background activ-
ities from other plasma proteases,34,54 and further
functionalizing NWs, which are superparamagnetic,30
with ﬁbrin-targeted ligands to allow contrast-en-
hanced magnetic resonance imaging (MRI) of indivi-
dual clots simultaneously with urine analysis.5557 To
allow clinical translation, we chose to use NWs because
we previously showed that they are well-tolerated by
mice, and similar FDA-approved formulations of iron
oxide nanoparticles (e.g., Ferridex) are already used in
patients;17,5863 however, thrombin substrates may
also be attached to other long-circulating nanoparti-
cles, such as dextran or liposomes, to prevent peptide
ﬁltration into urine until cleavage by proteases.
Looking forward, several clinical applications war-
rant further investigation with this approach. Because
sensing thrombin activity requires NWs to access the
sites of coagulation, the local architecture of the
vessels, clotting kinetics of the thrombi, and degree
of occlusion would all likely inﬂuence the rate of
peptide cleavage and clearance eﬃciencies of the
reporters.21,23,24 Therefore, additional studies that uti-
lize speciﬁc clinical models, such as deep vein throm-
bosis (DVT), would be important to determine the type
of clots this approach could be used to detect. Further,
whereas MRI or ultrasound can resolve anatomical
features of clots, they cannot discriminate stable
from extending thrombi without serial imaging.
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Related studies in atherosclerosis showed that throm-
bin activity could be used to diﬀerentiate stable from
severe plaques, highlighting the potential beneﬁts of
an activity-based measurement compared to imaging
alone.23 In summary, we believe this work further
broadens the repertoire of nanomedicines that
could be used for noninvasive monitoring of disease,
and we anticipate generalization to additional clin-
ical settings in which dysregulated thrombin activity
is prominent.
MATERIALS AND METHODS
Peptide Nanoworm Synthesis. Aminated iron oxide NWs were
synthesized according to previously published protocols.30
Peptides (biotin-eGvndneeGffsar(K-Flsc)GGfPRSGGGC, lower
case = D-isomer) were synthesized by the Tufts University Core
Facility peptide synthesis service. To conjugate peptides to
NWs, NWs were first reacted with succinimidyl iodoacetate
(Pierce) to introduce sulfhydryl-reactive handles. Cysteine ter-
minated peptides and 20 kDa polyethylene glycolSH (Laysan
Bio.) were then mixed with NWs (95:20:1 molar ratio) for one
hour at room temperature (RT) andpurified by fast protein liquid
chromatography. Stock solutions were stored in PBS at 4 C. The
number of fluorescein-labeled peptides per NWs was deter-
mined by absorbance spectroscopy using the absorbance of fluo-
rescein (490 nm) and its extinction coefficient (78000 cm1 M1).
For pharmacokinetic studies, NWs were first reacted with NHS-
VT750 (PerkinElmer) prior to PEGylation as above. For fluoro-
genic assays, thrombin substrates were synthesized with a
terminal fluorescein or VT750 in lieu of a reporter.
In Vitro Stability Assays. NWs (1 μM by peptide, 25 nM by NW)
were incubated in 10% fetal bovine serum at 37 C. At selected
time points, the particle size was measured by dynamic light
scattering (Malverin Zetasizer Nano Series) and the fluorescence
intensity was measured by microplate reader (SpectroMax
Gemini EM).
In Vitro Protease Assays. NWs (200 nM by peptide, 5 nM by NW)
weremixedwith human thrombin (2 μM), FVIIa (10 nM), FIXa (90
nM), FXa (160 nM), FXIa (31 nM), and activated protein C (60 nM),
all purchased from Haematologic Technologies, in a 384-well
plate at 37 C in activity buffers according to themanufacturer's
instructions and monitored with a microplate reader (SpectroMax
Gemini EM). For plasma studies, NWs were mixed with 50 μL of
control human plasma (Thermo Scientific) and 50 μL of 80 mM
CaCl2 (Sigma) or PBS. For thrombin inhibition experiments,
bivalirudin (Anaspec) was added to a final concentration of 5
mg/mL and preincubated for 2min prior to addition of NWs. For
the ELISA studies, NWs (100 nM by peptide, 2.5 nM by NW) were
incubated with thrombin for 10 min at 37 C, and cleaved
reporters (R1) were purified from NWs by centrifugal size
filtration (3 kDa MWCO).
ELISA Detection of Bifunctionalized Reporters. The bottom of
96-well plates (Thermo Scientific) were coated with either
0.8 μg/mL of anti-Flsc (GeneTex, GTX19224) or 0.4 μg/mL of
anti-Alex Fluor 488 (Invitrogen, A11094) diluted in PBS overnight
at 4 C. Plates were blocked with 1% w/v bovine serum albumin
(Sigma) in PBS for 1 h before 100 μL of samples were added.
Reporters captured on the plate were then detected by adding
100 μL of 0.2 μg/mL neutravidin-HRP (Pierce), developed with 50
μL TMB solution (Thermo Scientific) for 515min, and quenched
with 50 μL of HCl before the absorbance of the wells was
determined by microplate analysis (SpectraMax Plus, Molecular
Devices) at 450 nm. Plates were washed 3 with PBST between
each step, and incubation occurred at RT unless otherwise stated.
Characterization of Thromboplastin-Induced Thrombosis. Each vial
of thromboplastin containing 34 mg (from rabbit brain,
Sigma) was dissolved in 2 mL of PBS. To quantify fibrin deposi-
tion, bovine fibrinogen (Sigma) was reacted with 3-fold molar
excess of VT750 for 1 h at RT and purified by centrifugal size
filtration (100 kDa MWCO, Millipore). Swiss Webster mice
(Taconic) were lightly anesthetized with isofluorane and admi-
nistered mixtures of VT750-fibrinogen (1 nmol by VT750) with
thromboplastin (n = 3 mice per dose) via tail vein injections.
After 30 min, mice were euthanized by CO2 asphyxiation, and
organs were scanned on the LI-COR Odyssey Infrared Imaging
System. Fluorescence in each organwas quantified using Image
J software (NIH). To test thrombin inhibition, mice were intra-
venously administered bivalirudin (10 mg/kg) 5 min prior to
coinjection of thromboplastin. For histology, lungs were in-
flated with 4% paraformaldehyde, while all other organs were
incubated in 4% paraformaldehyde for 12 h at RT. All organs
were stored in 70% ethanol until paraffin-embedding, section-
ing, and staining (Koch Institute Histology Core).
NW Pharmacokinetics. To analyze NW and peptide pharmaco-
kinetics, mice were given either VT750-labeled NWs (5 μM
by VT750) or NWs conjugated with VT750-labeled peptides
(600 nM by peptide, 15 nM by NW) in conjunction with
thromboplastin. To analyze tissue sections by immunostaining,
NWs (600 nM by peptide, 15 nM by NW) and thromboplastin
(2 μL/g of b.w.) were administered to mice, and major organs
were harvested after 30 min. Representative lung sections were
stained for NWs (anti-Flsc primary, Invitrogen, A11090), fibrin
(Nordic, GAM/Fbg/Bio) and Hoechst (Invitrogen, H3569) before
analysis by fluorescence microscopy (Nikon Eclipse Ti).
Effect of Hydration State on Urine Concentration. The free reporter
R2 (biotin-eGvndneeGffsar(K-AF488)) was synthesized by the
Tufts University Core Facility peptide synthesis service.Mice (n=
5 mice) were anesthetized and injected subcutaneously with
a PBS bolus equivalent to 10% of their body weights. After
two hours, R2 (125 nm) was administered to mice via a tail
vein injection. Mice were placed over 96-well plates sur-
rounded by cylindrical sleeves for 30 min post-NW injection
to allow mice to void. Urine samples were stored at 80 C
until ELISA analysis.
Urinary Monitoring of Thrombosis. Experiments were conducted
in a paired setup. Thrombin-sensitive NWs (600 nM by peptide,
15 nM by NW) and R2 (125 nM) were coinjected into healthy
mice (n = 510 mice) to determine background protease
activity and placed over 96-well plates to collect urine. Five
days later, mice were again dosed with NWs, R2, and thrombo-
plastin before urine was collected from mice 30 min post-NW
injection. For thrombin inhibition experiments, mice were
intravenously administered bivalirudin (10 mg/kg) 5 min prior
to NW/R2 injections. Urine samples were stored at 80 C until
ELISA analysis.
Statistical Analyses. ANOVA analyses and Student's t-test were
calculatedwith GraphPad 5.0 (Prism). Pearson's r coefficient was
calculated with Excel (Microsoft Office).
All animal work was approved by the committee on animal
care (MIT, protocol #0411-036-14).
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